Introduction

51
Commercial aquaculture of most carnivorous fish species requires feeding these 52 species a high protein diet that currently is met with fish meal based diets. The sustainability 53 of this practice that requires high quantities of wild fish is accepted today but not for the long 54 term. Thus, it is recognized that the replacement of fish meal with plant raw materials 55 represents a sustainable alternative for the stability and further expansion of aquaculture. 56
However, such substitution remains problematic since feedstuffs of plant origin are naturally 57 rich in carbohydrates and species like the rainbow trout Oncorhynchus mykiss are considered 58 to be "glucose intolerant" (21, 42) due mainly to the prolonged hyperglycemia experienced 59 after a glucose load or intake of a carbohydrate-enriched meal (3, 24) . This intolerance is not 60 thought to be related to the absence of insulin, but nonetheless the mechanism(s) by which 61 insulin regulates plasma glucose levels in fish remain speculative, and the relative 62 contribution of the main peripheral tissues sensitive to this hormone remain to be clarified 63 (22) . Insulin receptors are present in the major insulin-responsive tissues including white 64 muscle, liver, and adipose tissues (4, 11, 27) , and up-regulation of insulin binding and 65 tyrosine kinase activities is observed after insulin treatment and carbohydrate-rich diets, 66 respectively (2, 11, 27) . Moreover, we have recently demonstrated that both fasted and high-67 carbohydrate fed rainbow trout respond to increased circulating exogenous insulin levels, and 68 that insulin improved glucose distribution and uptake by peripheral tissues, enhancing the 69 capacity of the animal to deal with a glucose load (31, 32) . 70
Metformin is an anti-diabetic drug used for the treatment of human type 2 diabetes to 71 improve glucose homeostasis by enhancing the insulin sensitivity mainly of the liver and 72 skeletal muscle (10). The major effect of metformin in mammals is to inhibit gluconeogenesis 73 by down-regulating hepatic gluconeogenic enzyme mRNA levels through activation of AMP-74 activated protein kinase (AMPK) (37). Metformin also improves glucose control by 75 implanted with two pumps (one for insulin, one for metformin), while the rest of groups were 126 implanted also with an extra pump infusing only saline solution. Additionally, the use of 127 mammalian insulin allows us to avoid the complications derived from the use of fish insulin, 128 because most of the piscine species express at least two insulin isoforms (5, 20) . Pump flow 129 rates were determined to be 0.39 μl·h -1 , which at 17ºC should provide sustained release of 20 130 mg·kg -1 ·day -1 of metformin and 26 µg insulin·kg -1 ·day -1 (0.7 IU insulin·kg -1 ·day -1 ) for 11 days. 131
Pumps were inserted into the peritoneal cavity through a 1.0 cm incision made in the ventral 132 midline at ca. 2.0 cm rostral of the pelvic fin. The incision was closed with one stitch and an 133
antibiotic gel was applied topically to the incision area. Pumps were implanted in the morning 134 and the next morning, fish were fed with a high carbohydrate diet (30% dextrin, 57% fish 135 meal, 10% fish oil, 1% attractant mix, 1% mineral mix, 1% vitamin mix). Fish were fed this 136 meal once per day (at 9 am, providing ~2% of the fish weight) for 5 days and sampled 6 h 137 after the last meal in order to evaluate fish metabolism at the peak of the postprandial 138 glycemia (25) . No symptoms of stress including alterations in feeding behavior were observed 139 as a consequence of pump implantation. 140
Tissue sampling 141
Trout were sacrificed by a sharp blow to the head. Blood was removed from the caudal 142 vein and centrifuged at 3,000 g for 5 min, and the recovered plasma was immediately frozen 143 at -20°C until analysed. Gut content of each fish was systematically checked to ensure that the 144 fish sampled had consumed the diet. Liver, perivisceral white adipose tissue and a sample of 145 dorso-ventral white muscle were immediately dissected, weighed and frozen in liquid 146 nitrogen and kept at -80°C pending analyses. 147
Biochemical and molecular analyses 148
Plasma glucose levels were determined using a commercial kit (Biomérieux, France) 149 adapted to a microplate format. Bovine insulin levels were measured using a commercial 150 ELISA kit (Mercodia, Sweden) as in Polakof et al. 2009 (33) . Tissue glycogen levels were 151 determined following the method of Keppler and Decker (15 
Statistical analysis 185
Results are expressed as means ± s.e.m. (n=6). Data were analyzed by one-way 186 ANOVA. When necessary, data were log-transformed to fulfill the conditions of the analysis 187 of variance. Post-hoc comparisons were made using a Student-Newman-Keuls test, and 188 differences were considered statistically significant at P<0.05. 189
190
Results
191
Plasma glucose levels are presented in Figure 1 . As predicted, fish fed the high 192 carbohydrate diet and implanted with saline pumps (control group) were hyperglycemic (~9 193 mM) when compared with the glycemia of fish fed commercial diets (~5 mM; data not 194 shown) (39) . Surprisingly, fish with insulin pumps had glycemic values comparable with the 195 control group. On the contrary, fish implanted with metformin-containing pumps alone or in 196 combination with insulin displayed significantly lower glycemia than the control group, being 197 7 and 6.5 mM, respectively. 198
Exogenous bovine insulin levels in the blood were consistent across fish with bovine 199 insulin-containing pumps averaging 6 ± 0.3 ng·mL -1 (~0.13 mIU·mL -1 ). 200
The phosphorylation status of Akt (serine 473) in liver, skeletal muscle and WAT is 201 presented in Figure 2 . Liver pAkt ( Fig. 2A ) levels were consistent across the different groups 202 with the exception of the group implanted with insulin + metformin pumps that demonstrated 203 a higher phosphorylation status than the control (saline) group. For muscle (Fig. 2B) and 204 WAT (Fig. 2C) , the results for pAkt were similar with the insulin-implanted group displaying 205 higher phosphorylation levels than the saline group (3 and 2-fold, respectively). 206 mRNA levels encoding hepatic enzymes involved in carbohydrate metabolism and 207 their respective specific activities are presented in Figure 3 . G6Pase mRNA levels ( ways. G6PDH mRNA levels were down-regulated in fish receiving metformin or insulin 239 alone, while activities were enhanced in the groups infused with metformin alone or in 240 combination with insulin. Finally, the mRNA levels of the transcription factor SREBP-1c-like 241 (Fig. 5H) were particularly sensitive to the presence of metformin in the infusion medium 242 being up-regulated in both the metformin and insulin + metformin treatments, while insulin-243 alone resulted in decreased mRNA levels. 244
Glycogen levels in liver, skeletal muscle and WAT are presented in Figure 6 . Liver 245 glycogen levels (Fig. 6A) were increased primarily when insulin was present, including 246 insulin alone and in combination with metformin. On the contrary, glycogen levels in skeletal 247 muscle ( Fig. 6B) and WAT (Fig. 6C ) decreased when compared with the control group in fish 248 receiving metformin alone or in combination with insulin. 249 250 Discussion 251
Metformin actions in rainbow trout, a "glucose intolerant" fish species, were 252 previously unknown. While some of the actions previously documented in mammals such as 253 inhibition of hepatic glucose output are not found in trout, we previously showed an improved 254 postprandial glycemic profile in metformin-fed trout probably linked to an increased 255 lipogenic activity (26). Moreover, in fasted trout, metformin exerted a paradoxical and 256 negative effect on insulin action (33). In order to unravel this paradox, we explored in the 257 present study whether metformin alone or in combination with insulin lowered plasma 258 glucose levels in rainbow trout fed a high-carbohydrate diet. The originality of the present 259 experimental design is to use both compounds together in order to maximise the previously 260 described actions when infused alone under the appropriate nutritional conditions (26, 33) . 261
We analysed the main targets of metformin reported in mammals and fish at both the 262 biochemical and molecular levels in 3 tissues known to modify glucose homeostasis, i.e. liver, 263 skeletal muscle and WAT. Generally a delay was observed between the molecular and 264 biochemical responses to the treatments, showing that for the complete functional response to 265 the treatment, the time of induction was important. 266
Lower glycemia levels in trout fed carbohydrates and infused with metformin 267
Rainbow trout infused with metformin for 5 days and fed a high carbohydrate diet 268 showed lower glycemia than fish fed the same diet and infused only with saline (vehicle) . 269
This lowering effect on glycemia exerted by metformin is in agreement with its use as an anti-270 diabetic drug in mammals (17, 36). As far as we are aware, this experiment is the first where 271 the gastrointestinal tract was not involved with metformin treatment in a chronic study. Thus, 272 the results obtained in the present study are exclusively due to changes in glucose uptake and 273 utilization by peripheral tissues, eliminating the known effects of this drug on intestinal 274 glucose absorption and oxidation (1). This glycemic effect of metformin was previously 275 observed in fish, although the administration method was different: transdermally for 276 zebrafish embryos (8), in the food for trout (26), or ip (acute) for carp (13). The fact that the 277 lowering effects on glycemia were observed in trout fed with carbohydrates as opposed to a 278 previous study using fasted trout injected acutely (ip) with glucose (33), confirmed that the 279 nutritional status of the animal is key for the metformin action and supports a possible indirect 280 involvement of the gastrointestinal tract on glucose homeostasis (29). 281
Metformin administration in trout in this study and in the fasted trout study (25) did 282 not affect the phosphorylation status of Akt in liver, skeletal muscle or WAT (not previously 283 tested). This is not too surprising as the main signalling pathway utilized by metformin to 284 exert its actions in mammals is thought to be LKB1 and the AMP-dependent protein kinase 285 (37). Unfortunately, none of these proteins could be detected in our in vivo study utilizing 286 mammalian antibodies. 287
The major effects of metformin in mammals include the inhibition of hepatic 288 gluconeogenesis, increased glucose uptake into muscle, and an anti-lipolytic effect on adipose 289 tissue (10). Although some of these effects are described in fish (8, 33), others like an 290 increased FAS mRNA levels in liver seem to occur only in the piscine model (26). Metformin 291 actions on fish WAT were previously not explored. Globally, we reported that rainbow trout 292 infused with metformin showed an increased lipogenic potential at both the biochemical and 293 molecular levels in liver and WAT. The increased hepatic mRNA levels of FAS induced by 294 metformin were previously reported in fed trout (26), and based on the data presented here the 295 changes in this enzyme may be primarily responsible for the hypoglycemic effects of this 296 drug in trout. Further support for these results was found with SREPB-1c-like, which 297 followed the changes in lipogenic potential and is known to regulate lipogenesis at the 298 molecular level (40). The fact that metformin has no effect on rat adipocytes lipogenesis) (34) 299 suggests that the mechanism by which metformin acts in fish could be different from that 300 described in mammals. However, this is not the only metabolic event that could improve 301 glycemic profiles under these conditions. Based on the lower activities and mRNA levels of 302 hepatic G6Pase, a decreased capacity to export glucose to the blood from the liver is 303 predicted. A lower ability to export glucose from the liver was previously reported in fasted 304 trout infused with metformin (33) and is consistent with the effects described in mammals 305 (18, 36) . However, increased PEPCK activities, together with the previously reported high 306 mRNA levels for this enzyme in trout fed metformin (26) suggest that at least in salmonids, 307 reduced hepatic glucose output is related to a decreased glycogen breakdown rather than with 308 a reduced gluconeogenic potential, one of the known actions of metformin in mammals (16) 309 and at least zebrafish (8). On the other hand, we found enhanced mRNA levels for GLUT4 in 310 skeletal muscle and WAT, suggesting an increased potential for glucose uptake from plasma 311 by peripheral tissues in metformin-infused trout. 312
Infused insulin has no effect on plasma glucose levels in trout fed carbohydrates 313
The major result obtained in trout infused with insulin and fed the high carbohydrate 314 diet was an absence in glycemic changes when plasma values were compared with the saline 315 infused control group. These results are surprising, since in other studies where insulin was 316 administrated to fish fed similar diets, significant hypoglycemia was observed with respect to 317 the saline-infused control group (23, 41). However in both studies the insulin dose was higher 318 and acutely administrated in contrast to the present study where physiological insulin doses 319 (19) were infused over a longer time period. Chronic exposure to insulin is able to create 320 insulin insensitivity and resistance in mammals, resulting in prolonged hyperglycemia and 321 thus impaired glucose control (14). A similar phenomenon was described by us in the skeletal 322 muscle of fasted rainbow trout, where Akt phosphorylation status was depressed in the 323 insulin-infused fish (32). However, in the present study the nutritional status of the animal 324 seems to be key in protecting the insulin signaling pathway from constant insulin stimulation, 325 since Akt phosphorylation was enhanced in the insulin-treated fish when compared with the 326 control group in both skeletal muscle and WAT, the two insulin-sensitive tissues assessed. 327
Actually, some of the parameters assessed including increased hepatic glycogen levels and 328 lipogenic potential in liver and WAT, suggest that insulin was exerting its predictable effects 329 (22). On the other hand, the absence of changes in genes related to glucose uptake and 330 phosphorylation and changes in glycogen content in insulin-sensitive peripheral tissues 331 (skeletal muscle and WAT) indicates that some other reported effects of the hormone (4, 22) 332 are not taking place under the conditions of our study. The duality of these results related to 333 global glucose homeostasis in rainbow trout must be investigated in future studies. However, 334 excess circulating glucose due to the high carbohydrate proportion in the food can not be 335 discarded as responsible, at least in part, for the lack of changes in glycemia in the insulin-336 infused trout. 337
Insulin plus metformin effects on carbohydrate-fed trout are tissue-dependent 338
We hypothesized in this study that the combination of the anti-diabetic drug 339 metformin and the hypoglycemic hormone insulin would improve glucose homeostasis in 340 rainbow trout fed a high-carbohydrate diet. The effects exerted by the combination of 341 metformin and insulin were strongly tissue-dependent, and often a combination between the 342 effects of the product infused individually. Globally, we found that none of the effects exerted 343 by metformin alone on glucose metabolism in skeletal muscle are observed when the drug is 344 combined with insulin. Actually, the absence of changes in glucose uptake, phosphorylation 345 and glycogen storage match the results obtained with insulin alone, suggesting a predominant 346 action of insulin on this tissue, traditionally known to be insulin-sensitive (12, 22) . The 347 exception was that Akt phosphorylation status was not stimulated even when insulin was 348 infused, in agreement with a previous study in fasted trout (33). Despite the recurrent negative 349 interaction between metformin and insulin in this species, the mechanism by which this take 350 place remains to be elucidated. In this case, we suggest that whatever mechanism is 351 responsible it does not involve the phosphorylation status of Akt, as the phosphorylation 352 status was similar to that observed in the insulin-infused group. As opposed to the muscle 353 results, metformin exerts predominant effects on WAT glucose metabolism. Some of the 354 parameters not affected by insulin including glucose uptake and glycogen levels were 355 increased by the combination of metformin and insulin, as observed in the metformin-alone 356 group. On the other hand and as occurred in skeletal muscle, the infusion of metformin 357 together with insulin blocked Akt phosphorylation noted with insulin alone, confirming the 358 multi-tissue negative effect of this drug on the insulin signaling pathway. The fact that in trout 359 the WAT is also an insulin-sensitive tissue (4, 22) gives more importance to this interaction, 360
suggesting that the glucose homeostasis in this species could be compromised at least in the 361 WAT when metformin is co-administrated with the insulin. Finally, the changes observed in 362 the liver did not correspond clearly to any of the treatments alone. Thus, while Akt 363 phosphorylation was not altered by insulin or metformin alone, their combination resulted in a 364 significantly higher Akt phosphorylation status than in the control group. This result agrees 365 with that described in mammals where metformin is utilized to improve insulin action, 366 reducing insulin resistance (7). On the other hand, the increased lipogenic potential observed 367 with respect to the control group in both liver and WAT in the insulin plus metformin 368 compared with the independent treatments, was not altered by the interaction. Other aspects 369 of the hepatic glucose metabolism were differentially affected by the co-infusion of insulin 370 and metformin: the glucose export capacity was reduced, as in the metformin-alone group, 371 while the glycogen levels were increased, as in the insulin-alone group. As a whole, and in a 372 very interesting way, we have found that the metformin plus insulin group presented all the 373 effects expected for the combined treatment, i.e. a better glycemic phenotype (lower glycemia 374 levels) but also an increased ability to store the excess glucose as glycogen and lipids. 375
Additionally, this is the first time in which we observed, in contrast to a previous study with 376 fasted trout (33), an improved insulin sensitivity in fish infused with metformin and insulin, as 377 occurs with the type II diabetic patients (35). 378
Perspectives and Significance 379
The present study had as its main objective to improve dietary glucose utilization and 380 homeostasis in rainbow trout, a 'glucose intolerant' species. To accomplish this, trout were 381 infused with metformin (a recognized anti-diabetic drug) and insulin (hypoglycemic 382 hormone) and fed a high proportion of carbohydrates; we expected that the combined effect of 383 both compounds would have a positive impact on glucose homeostasis. Thus, trout infused 384 with insulin and metformin can effectively utilize dietary glucose at the hepatic level, 385 including lowered glycemia, increased insulin sensitivity and glucose storage capacity, 386 combined with reduced glucose output, as documented in mammals (6) and zebrafish (8). The 387 fact that glucose utilization could be improved by the insulin plus metformin combination 388 implies that some of the pathways involved in glucose utilization in the liver of the control 389 group may not be working effectively or as in glucose-tolerant species, leading to the poor 390 glucose utilization observed in trout fed with carbohydrates. However, the responses of the 391 other tissues to the combined treatment did not necessarily follow that of the liver. In the two 392 insulin-sensitive tissues (WAT and skeletal muscle) we observed decreased insulin sensitivity 393 with the combined treatment, resulting in the absence of changes at the metabolic level in 394 skeletal muscle and an increased potential for glucose uptake and storage in WAT. While 395 some of our results demonstrated that part of the negative interactions observed previously in 396 trout (33) were dependent on the nutritional status, there were important tissue-specific 397 variations in the response resulting in an improvement in glycemia but not complete 398 normoglycemia. We can, therefore suggest that the poor utilization of a diet containing a high 399 proportion of carbohydrate by the rainbow trout could at least be partially improved by a 400 combination of insulin plus metformin, and that the glucose intolerance observed in this 401 species could be in part due to some of the downstream components of the insulin and 402 metformin signalling pathways. The mammalian-like effect of metformin in trout also support 403 that at least some of the components involved in the metformin action in mammals (43) 
